Monoamine oxidase inhibitors as a class

Class Monoamine oxidase inhibitor
Chemistry
chemically diverse group; eg. tranylcypromine is a substituted amphetamine
Routes of administration

Oral only

Absorption
Rapidly and completely absorbed; bioavailability ~ 10% (selegiline) to 50% ( moclobemide)
Solubility
Reasonably water-soluble
Distribution
VOD=1.75L/kg(tranylcyproimine) to 25 L/kg (selegiline) probably highly protein-bound (eg. to MAO!)
Metabolism
Extensively metabolised, probably in the liver; some of the metabolites have activity, eg. selegiline is metabolised into amphetamine and methamphetamine.
Elimination
Minimum renal excretion as unchanged drug
Time course of action
Half-life is only about 2-4 hours, but this does not have any relationship to the duration of their effect
Target receptor

Monoamine oxidase A and B

Mechanism of action

By binding to both kinds of monoamine oxidase enzymes MAOIs increases the availability of catecholamine neurotransmitters (i.e. mainly noradrenaline and dopamine). Some do this in a completely irreversible fashion.

Clinical effects

Hypertensive crises, hepatotoxicity, seizures, hypoglycaemia, mania, serotonin syndrome. Dangerous pharmacodynamic interactions with other antidepressants and monoaminergic drugs, as well as foods that act as catecholamine precursors

Literature reference

Ulrich et al (2017)

CICM details of understanding Level 3
Mentioned around Deranged Physiology
Related SAQs

Question 9(p.2) from the first paper of 2009 (compare and contrast classes)

Question 3 from the second paper of 2007 (TCA overdose)